NCT04226274View on ClinicalTrials.gov

A Study of the Safety of REN001 in Patients With McArdle Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

December 10, 2019

Primary Completion Date

October 11, 2021

Study Completion Date

October 11, 2021

Conditions
McArdle Disease
Interventions
DRUG

REN001

Once daily for 12 weeks

Trial Locations (2)

28041

Instituto de Investigación Hospital 12 de Octubre, Madrid

WC1 3BG

National Hospital for Neurology and Neurosurgery, Queens Square, London

All Listed Sponsors
lead

Reneo Pharma Ltd

INDUSTRY

NCT04226274 - A Study of the Safety of REN001 in Patients With McArdle Disease | Biotech Hunter | Biotech Hunter